Unexpected reaction of “wild-type” gastrointestinal stromal tumor to imatinib: case report and literature review
BackgroundMost of gastrointestinal stromal tumors (GISTs) are driven by mutations in the KIT/PDGFRA genes and can benefit from TKIs treatment. However, a small subset of GIST (10%-15%) are called “wild-type” GISTs due to the lack of these mutations. Theoretically, they would not benefit from TKIs tr...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Frontiers Media S.A.
2024-01-01
|
| Цуврал: | Frontiers in Oncology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1334784/full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|